There are many problems associated with plasmid DNA that may limit its use in systemic gene transfer. These problems could be solved by the use of synthetic genes. As a model to test the feasibility of using synthetic genes for gene therapy, we PCR-amplified a fragment containing the CMV promoter, the luciferase gene and a polyadenylation signal. The in vivo expression efficiency of the PCR fragment was determined by using two different methods, a hydrodynamics-based gene transfer of naked DNA to the liver and LPD (a lipid-based vector) mediated gene transfer to the lung. Our results show that linear fragments are at least as active as plasmid DNA following systemic delivery by LPD.
In recent years, many nonviral strategies have been developed for gene therapy. 1, 2 To transfer genes sucessfully, a substantial amount of effort has been devoted to the improvement of delivery vehicles in order to make them highly efficient, but not immunogenic or cytotoxic. However, less attention has been paid to the problems that are associated with the DNA that is being delivered. Many factors limit the efficacy of plasmid DNA in systemic gene transfer. One problem associated with plasmid DNA is the complexity of production. In order to produce a large quantity of plasmid DNA, a gene has to be cloned into an expression vector then transformed into, grown in, and eventually purified from bacteria. This standard method of plasmid production takes much time and is very labor-intensive. Production of plasmid DNA with reproducible purity and biological activity by this method remains to be difficult due to contamination, particularly by endotoxin. Humans and most primates are highly sensitive to endotoxin 3 with high doses causing circulatory collapse. 4 Therefore, endotoxin contamination of plasmid DNA has become an important safety concern for human gene therapy. In addition, endotoxin can severely decrease transgene expression in the transfected cells. 5 Transfection activity may vary from batch to batch due to various degrees of endotoxin contamination.
In addition to production problems, bacterially derived plasmid DNA is recognized as foreign in vertebrate However, PCR fragments are much less inflammatory than plasmid DNA as shown by a three-fold reduction in serum levels of both TNF-␣ and IL-12. Our results also showed that PCR fragments are highly efficient in liver gene transfer following systemic administration in a large volume. Thus, these results support the idea of using synthetic genes for gene therapy. Since gene sequence can be easily obtained as a PCR fragment, our results also imply that it may provide a useful and convenient method for determining the physiologic function of a putative gene in intact animals. Gene Therapy (2001) 8, 71-74.
cells. [6] [7] [8] This is due to the structural difference between mammalian and plasmid DNA. In bacterial DNA CpG dinucleotides appear at an expected frequency of one out of 16 nucleotides. Mammalian DNA differs from bacterial DNA in that the frequency of CpG dinucleotides is significantly reduced compared with that of bacterial DNA with a frequency of one out of 64 nucleotides. In addition, about 75% of the CpGs in mammalian DNA are methylated at the cytosine position, while CpGs are largely unmethylated in bacterial DNA. 9 Due to these structural differences, bacterially derived DNA stimulates a potent immune response in mammalian systems. 10 These stimulatory effects include the triggering of B cell proliferation, resistance to apoptosis, and release of interleukin 6 (IL-6); natural killer cell secretion of interferon ␥ (INF-␥) and increased lytic activity; and monocyte-macrophage secretion of INF-␣/␤, IL-6, IL-12, granulocyte-macrophage colony-stimulating factor (GM-CSF), chemokines, and tumor necrosis factor ␣ (TNF-␣). [10] [11] [12] [13] The most potent CpG sequences in plasmid DNA are the ones that are flanked by two 5Ј purines (optimally a GpA) and two 3Ј pyrimidines (optimally a TpC or TpT). Clearly, the strong stimulatory effect triggered by the unmethylated CpG sequences in plasmid DNA is a potential problem in gene therapy. Our laboratory previously reported that intravenous administration of cationic lipid-protamine-DNA complexes (LPD) induce the production of large quantities of proinflammatory cytokines, including IL-1␤, IL-12, INF-␥, TNF-␣. 14, 15 These cytokines can be toxic, including lethal effects in experimental animals, 16 and cause inhibition of transgene expression. 15, 17 These problems might be solved by the use of synthetic genes, ie DNA synthesized chemically. This method opens the possibility of generating transcriptionally active fragments that can be directly used without any cloning. More importantly, using synthetic genes makes it possible to amplify a fragment with a reduction in the total CpG sequences by eliminating all nonessential regions within the plasmid backbone. This reduction in the total CpG motifs should result in a decreased inflammatory response, while not affecting transgene expression. There are additional advantages in using synthetic genes that are not shared by plasmid DNA. First, the purification of chemically synthesized DNA is well developed. Second, chemical modification can be manipulated according to specific needs. For example, stability of the gene could be improved by incorporating phosphorothioated bases to the ends of these synthetic genes.
This study is designed to address the above issues concerning plasmid DNA and to prove the concept of using synthetic genes for gene therapy. We have previously shown that cells can be efficiently transfected by PCR fragments in vitro when delivered by a cationic lipidic vector. 18 To further investigate the possibilities of synthetic genes for gene therapy in vivo, we designed two primers to PCR amplify a 3.1 kb region of the plasmid CMV-Luc that contains the CMV promoter, the luciferase gene and a polyadenylation signal ( Figure 1) .
As an initial approach to determine if synthetic genes can be used in gene therapy, we tested whether our PCRamplified fragment is as active as plasmid DNA. Therefore, LPD nanoparticles containing 6.7 pmols of either fragment DNA or plasmid DNA were intravenously administered and the level of gene expression in the lung was determined at various time-points. Lung was chosen because it is the organ that shows the highest level of gene expression following intravenous administration of LPD. 19 Both plasmid and fragment gave similar levels of gene expression at all time-points observed ( Figure 2 ). The highest level of gene expression was obtained at 8 h after injection and declined thereafter. LPD containing linearized plasmid DNA showed similar levels of gene expression (data not shown).
It has been shown that a decrease in the CpG content results in a decreased inflammatory response to in vivo administration of cationic lipid/DNA complexes. 20 , 21 We therefore hypothesized that our PCR product should cause less cytokine induction when delivered by LPD. To test this hypothesis we determined serum cytokine levels in mice after systemic delivery of LPD containing either plasmid DNA or PCR-amplified DNA. Specifically, the levels of TNF-␣ and Il-12 were determined by ELISA at 2 and 6 h, respectively. These cytokines are maximally induced following LPD administration at these times. Use of PCR fragments resulted in a three-fold decrease in the serum level of both TNF-␣ and IL-12 as compared with the plasmid DNA (Figure 3 ). These studies demonstrate that use of DNA containing only the parts essential for gene expression is a good approach and useful therapeutic strategy to improve cationic lipid-mediated intravenous gene delivery. In addition, these studies emphasize the feasibility of using chemically synthesized genes.
Proinflammatory cytokines such as TNF-␣ have been shown to play a role in transgene inactivation. 15, 17, 21 We initially hypothesized that a reduction in serum TNF-␣ levels would result in longer duration of gene expression following LPD administration. 15 However, we did not observe any increase in duration of transgene expression. One possible explanation is that although the level of TNF-␣ is decreased, the levels are still too high for a significant enhancement of transgene expression to be seen. Further work needs to be done in order to reduce cytokine levels even further.
Advancements in vector development will not only further improve human gene therapy, but will also provide a useful tool for studying the function of unknown genes. The human genome project will lead to the discovery of many genes of unknown function. The next significant challenge is to assign functions to these genes. In vivo transgene expression for gene function studies will require the development of a method that is simple and cost-effective. Although the most intensively studied methods for the introduction of exogenous genes into animal cells utilize a viral or nonviral vector, 22 ,23 the direct use of naked DNA is currently under investigation as an alternative approach. [24] [25] [26] [27] [28] [29] [30] [31] One of the greatest advantages of using naked DNA directly is that long and laborious steps for virus production or for preparation of nonviral vectors can be avoided, making this approach less time-consuming. Recently, two independent groups, 31, 32 have developed a hydrodynamics-based procedure for achieving a high level of transgene expression by systemic administration of naked DNA. In this method, DNA to be delivered is diluted in a large volume of saline (7.3% of body weight for mice) and injected rapidly into the tail vein. This results in gene delivery primarily to the liver by developing a high hydrostatic pressure in the inferior vena cava. It forces the DNA solution to flow into tissues in a direction that is opposite to that of the regular circulation. The solution will mostly flow into the liver because it is the largest organ in the body and has an expandable structure. This will result in the in vivo production of a large quantity of the protein of interest in the liver. The effects of this overexpression may provide some insights into the function of the protein. Alternatively, significant quantities of purified protein for in vitro studies can be extracted and purified from the livers of mice transfected in this manner.
It has been proposed that this method could be used for determining the function of newly discovered genes. 31, 32 We proposed to replace plasmid DNA with a PCR fragment to further simplify the procedure. To demonstrate that plasmid DNA can be substituted by PCR Gene Therapy amplified fragment in this system, we delivered 2.7 pmols of either PCR amplified fragment or plasmid DNA into mice using the hydrodynamics based gene transfer method and compared the level of gene expression. Following gene delivery, luciferase activity in the liver was determined at different time-points. As shown in Figure  4 , gene expression with either PCR fragment or plasmid DNA reached a maximum at 8 h. Luciferase activity remained greater than 10 6 RLU/mg for at least 6 days with fragment DNA, while plasmid DNA decreased to 10 5 RLU/mg at the same time-point. At all time-points greater than 3 days, fragment DNA showed higher levels of luciferase activity than plasmid DNA. Based on this slower rate of decline in gene expression, we believe that PCR fragments may provide somewhat longer lasting gene expression. This might be due to, among others, the more efficient integration of linear DNA fragment into the genomic material as compared with plasmid. 33, 34 This possibility is currently under investigation.
These results suggest that the hydrodynamics-based procedure is a simple, convenient and efficient way to introduce and express genes in vivo by systemic administration of PCR amplified DNA. Using the above method, cloning can be avoided altogether and a putative gene of unknown function can be PCR amplified from genomic DNA or a cDNA library and delivered into mice in a matter of hours instead of days. Overall, this method could be useful for studying the function of new genes discovered by the human genome project and other gene discovery programs worldwide.
In summary, we have shown that an efficient in vivo gene transfer can be achieved using PCR fragments. Our results not only support the idea of using synthetic genes for gene therapy, but also provide a useful and convenient method for determining the physiologic function of a putative gene in intact animals. 
